Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 1 | Cell & Bioscience

Fig. 1

From: Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?

Fig. 1

PD-L1 on either tumor cells or host immune cells is proposed to function in preventing T cell-mediated tumor killing. PD-1 is highly expressed in exhausted effector T cells. PD-L1 is constitutively expressed in some tumors and host immune cells, and its expression can be induced or maintained by many factors. PD-1-PD-L1 interaction drives T cell dysfunction, which results in a weaker tumor killing ability in effector T cells. Therefore, anti-PD-1/PD-L1 antibodies-mediated specific blockade of the PD-1/PD-L1 pathway can enhance antitumor immunity

Back to article page